Biotechnology and the Global Financial Crisis
Emergent biotechnology companies are very reliant on capital, often having less than two years capital on hand. Like other businesses […]
Emergent biotechnology companies are very reliant on capital, often having less than two years capital on hand. Like other businesses […]
I’m working on an International Biotechnology ranking and comparison for a well-known publication, and am looking for data sets comparing
Post your content on BiotechBlog and have it syndicated across the web. Send me a pitch using the contact form. Guidelines
Join the Journal of Commercial Biotechnology discussion group on LinkedIn: http://www.linkedin.com/groups?gid=1241807 This group focuses on the biotech industry. The audience
Join the Journal of Commercial Biotechnology Discussion Group Read Post »
Those who have been following this blog for long enough probably know what it means when posting slows down —
The July 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to
Journal of Commercial Biotechnology — October 2008 Read Post »
Guest content from John Avellanet, managing director and principal of Cerulean Associates: Intellectual Property Theft on the Rise By John
Two upcoming talks on biotechnology career development strategies at Johns Hopkins campuses: Homewood Campus Friday, Oct. 17th 2008 5:30-7:30pm Remsen
I’d like to build on the success of my “Best Practices in Biotechnology…” book series by producing more edited compilations
Seeking experienced industry insiders for book series Read Post »
A lot of people have been asking my opinion on when a concise generic biologic regulatory pathway will emerge in
When will the U.S. develop concise generic biologic rules? Read Post »
Get new actionable insights and updates from BiotechBlog